Biotech Takeover Targets Wall Street Eyes After Apogee Deal
AbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
Index funds generally provide more control over allocations than target date funds, which automate drift. This intro explains what that means in practice.
28,480 articlesAbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
Many altcoins under $1 could offer outsized gains, but they also carry significant risk. This guide provides a practi...
A wave of selling hit AI-related shares after a blog post framed AI gains as 'science fiction.' Behavioral finance ex...
A high-conviction bet on a Chinese logistics platform faced a sharp stock drop. This article explains why the fund wa...
A nuclear startup teams with a national lab to speed up reactor design using AI. This piece breaks down what it could...
Two powerhouse ideas could propel your portfolio toward the next decade: a campus-wide AI infrastructure leader and a...
A Nobel Prize–winning economist says U.S. democracy hinges on two policy shifts tied to AI and inequality. He outline...
Global policymakers wrestle with ai sovereignty as the economy and everyday life increasingly rely on frontier AI. Th...
A modern bank-heist tale hinges on digital breadcrumbs. Learn how a trail built from YouTube repair videos and locati...
Bitcoin could mount a major rally as a liquidity wave from Washington enters the system. A market note outlines two p...
Disney is testing a bold move: a unified app that ties together its streaming, parks, and products. This article brea...
As 2026 unfolds, investors debate what’s best crypto between XRP, Solana and BNB, weighing use cases, network upgrade...